Leukemia, Myelocytic, Acute
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).
|
31661339 |
2020 |
MYELODYSPLASTIC SYNDROME
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.
|
16210092 |
2005 |
Myelodysplasia
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.
|
16210092 |
2005 |
Gilles de la Tourette syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The findings indicate that the AADAC gene c.361 + 1G > A variant may be a potential candidate factor for TS development, though further investigations are warranted.
|
29253601 |
2018 |
Leishmaniasis, Cutaneous
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Salvage therapy with Sodium chlorosum (formerly DAC N-055) for cases of refractory lupoid cutaneous leishmaniasis: results from a compassionate use study with 0.09% Sodium chlorosum in amphiphilic basic cream.
|
31779597 |
2019 |
Acute monocytic leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).
|
31661339 |
2020 |
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Decitabine (5-Aza-2'-deoxycytidine, DAC), an anti-leukemic drug, is effective in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
|
30210693 |
2018 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
DAC (5-aza-2-deoxycytidine) is an antitumor drug useful to lung cancer, myelodysplastic disorders, myelodysplasia and acute myeloid leukemia.
|
25611377 |
2015 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
This study, the first to investigate the relationship between TERT methylation and telomerase activity in leukemia cells, demonstrated a differential methylation pattern and response to DAC in three AML cell lines.
|
22517724 |
2012 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
The clinical activity of decitabine (5-aza-2-deoxycytidine, DAC), a hypomethylating agent, has been demonstrated in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients.
|
30793488 |
2019 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Undergoing allo-HSCT significantly improved the LFS and OS for the entire group of patients with AML in CR1, along with the DAC induction subgroup and for the group with unfavorable cytogenetics aged 41-60.
|
26149802 |
2015 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Preclinical data indicate that DAC is much more effective against human AML than ARA-C.
|
23660386 |
2013 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
The hypomethylating agents azacitidine (Vidaza®, AZA) and decitabine (Dacogen®, DAC) have been approved for the treatment of AML patients, but their mechanisms of action are poorly understood.
|
28404876 |
2017 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
The promoter of p73 was hypermethylated in AML cell lines in vitro and in primary AML cells ex vivo but not in DAC-resistant epithelial cells.
|
16193303 |
2005 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Cytotoxic T cells specifically recognizing MAGE-A family and NY-ESO-1 clustered at the tumor site in mice pre-treated with DAC and resulted in tumor growth suppression, while it was not observed in mice without DAC pre-treatment.
|
25301731 |
2014 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The p-GSK3β (Ser9) protein level in Caki-2 cells was significantly down-regulated, while the DNA fragmentation rate increased after treatment with 5 μM DAC at 96 h. Our data show that sFRP2 functions as a tumor suppressor gene in RCC and that its restoration may offer a new therapeutic approach for the treatment of RCC.
|
23975733 |
2013 |
MYELODYSPLASTIC SYNDROME
|
0.060 |
Biomarker
|
group |
BEFREE |
The clinical activity of decitabine (5-aza-2-deoxycytidine, DAC), a hypomethylating agent, has been demonstrated in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients.
|
30793488 |
2019 |
MYELODYSPLASTIC SYNDROME
|
0.060 |
Biomarker
|
group |
BEFREE |
DAC (5-aza-2-deoxycytidine) is an antitumor drug useful to lung cancer, myelodysplastic disorders, myelodysplasia and acute myeloid leukemia.
|
25611377 |
2015 |
MYELODYSPLASTIC SYNDROME
|
0.060 |
Biomarker
|
group |
BEFREE |
Low-dose demethylating agents such as 5-aza-2'-deoxycytidine (decitabine, DAC) and 5-azacytidine (azacitidine, Vidaza) have been explored for the treatment of myelodysplasia, acute myeloid leukemia, and hemoglobinopathies since the early 1980s, aiming to revert a methylator phenotype.
|
16292549 |
2005 |
MYELODYSPLASTIC SYNDROME
|
0.060 |
Biomarker
|
group |
BEFREE |
Decitabine (5-Aza-2'-deoxycytidine, DAC), an anti-leukemic drug, is effective in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
|
30210693 |
2018 |
MYELODYSPLASTIC SYNDROME
|
0.060 |
Biomarker
|
group |
BEFREE |
During the last 10 years, three European phase II studies were performed to investigate the treatment of elderly patients with myelodysplastic syndrome (MDS) with low-dose 5-aza-2'-deoxycytidine (decitabine, DAC).
|
16211386 |
2005 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Functional assays, such as flow cytometry, cytotoxicity assays and ELISA, were performed to determine the demethylation agent, decitabine (5-aza-2'-deoxycytidine, DAC)-treated cancer cell improved antigen specific T cells response.
|
30797153 |
2019 |
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrast-enhanced lesions on brain magnetic resonance imaging.
|
28450896 |
2017 |
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Expert commentary: Monthly daclizumab-beta [DAC-beta, formerly daclizumab high yield process (DAC HYP), approved as ZINBRYTA®, which has a different form and structure than an earlier form of daclizumab], is an effective and convenient treatment option for patients with relapsing forms of MS who have failed other treatment, or as a first-line option in highly active MS patients.
|
28803486 |
2017 |